Stone RM - Search Results

1

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Raza A, et al. Among authors: stone rm. Blood. 2008 Jan 1;111(1):86-93. doi: 10.1182/blood-2007-01-068833. Epub 2007 Sep 24. Blood. 2008. PMID: 17893227 Free article. Clinical Trial.

2

Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. Andreeff M, et al. Blood. 1992 Nov 15;80(10):2604-9. Blood. 1992. PMID: 1421378 Free article. Clinical Trial.

3

Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.

Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Rubin EH, et al. Among authors: stone rm. J Clin Oncol. 1992 Jun;10(6):948-53. doi: 10.1200/JCO.1992.10.6.948. J Clin Oncol. 1992. PMID: 1588374 Clinical Trial.

4

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, et al. Larson RA, et al. Among authors: stone rm. Blood. 1995 Apr 15;85(8):2025-37. Blood. 1995. PMID: 7718875 Free article. Clinical Trial.

5

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.

Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Bernstein SH, et al. Among authors: stone rm. J Clin Oncol. 1996 Sep;14(9):2486-94. doi: 10.1200/JCO.1996.14.9.2486. J Clin Oncol. 1996. PMID: 8823327

6

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA. Larson RA, et al. Among authors: stone rm. Blood. 1998 Sep 1;92(5):1556-64. Blood. 1998. PMID: 9716583 Free article. Clinical Trial.

7

A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.

Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. Schiffer CA, et al. Among authors: stone rm. Blood. 2000 Apr 15;95(8):2530-5. Blood. 2000. PMID: 10753831 Free article. Clinical Trial.

8

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL; World Health Organization(WHO) international working group. Cheson BD, et al. Among authors: stone rm. Blood. 2000 Dec 1;96(12):3671-4. Blood. 2000. PMID: 11090046 Free article.

9

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

Baer MR, Stewart CC, Dodge RK, Leget G, Sulé N, Mrózek K, Schiffer CA, Powell BL, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD. Baer MR, et al. Among authors: stone rm. Blood. 2001 Jun 1;97(11):3574-80. doi: 10.1182/blood.v97.11.3574. Blood. 2001. PMID: 11369653 Free article.

10

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, Bloomfield CD, Schiffer CA. Stone RM, et al. Blood. 2001 Aug 1;98(3):548-53. doi: 10.1182/blood.v98.3.548. Blood. 2001. PMID: 11468148 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

538 results

Search Page

Filters